{
    "nctId": "NCT06321666",
    "briefTitle": "Response Evaluation of Cancer Therapeutics in Metastatic Breast Cancer to the Bone",
    "officialTitle": "Response Evaluation of Cancer Therapeutics in Metastatic Breast Cancer to the Bone: A Whole Body MRI Study MILANO : RESPECT-MI",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "DIAGNOSTIC",
    "enrollmentCount": 58,
    "primaryOutcomeMeasure": "Proportion of disease progression in bone metastasis identified by WB-MRI prior to CT scan",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histological diagnosis of breast cancer\n* Single or multiple bone metastases (additional extraosseous or non-bony metastatic disease permitted)\n* Due to start a new line of either hormone therapy or chemotherapy (use of bisphosphonates / denosumab or targeted agents e.g. trastuzumab in addition to hormone therapy / chemotherapy permitted)\n* Aged 18 and over\n* Life expectancy of over 6 months\n* No current active malignancy other than breast cancer\n\nExclusion Criteria:\n\n* Radical treatment to sole site of metastatic disease e.g. Cyberknife to solitary bone metastasis\n* Absolute contraindication to MRI studies, CT scans, bone scans or FDG-PET/CT\n* Pregnancy\n* Psychological, familial, sociological or geographical conditions that would hamper compliance with the study protocol; such conditions should be discussed with the patient as part of the informed consent process.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}